EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis

Aniket Saini, Pooja A Chawla iD

European Journal of Neurology · 2024-02 · 31 (2)

DOI: 10.1111/ene.16140 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Neurology, online erschienen am 17.11.2023. Verfasst von Aniket Saini und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, ISF College of Pharmacy, Moga, Punjab, India. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that primarily affects adults, characterized by muscle weakness resulting from the specific death of motor neurons in the spinal cord and brain. The pathogenesis of ALS is associated with the accumulation of mutant superoxide dismutase 1 (SOD1) proteins and neurofilaments in motor neurons, highlighting the critical need for disease‐modifying treatments. Current therapies, such as riluzole and edaravone, provide only symptomatic relief. Recently, tofersen gained approval from the US FDA under the brand name Qalsody as the first and only gene therapy for ALS, addressing a significant pathological aspect of the disease.

Methods

We carried out a literature survey using PubMed, Scopus, National Institutes of Health, and Biogen for articles published in the English language concerned with “amyotrophic lateral sclerosis”, pathophysiology, current treatment, treatment under clinical trial, and the newly approved drug “tofersen” and its detailed summary.

Results

A comprehensive review of the literature on the pathophysiology, available treatment, and newly approved drug for this condition revealed convincing evidence that we are now able to better monitor and treat ALS.

Conclusions

Although treatment of ALS is difficult, the newly approved drug tofersen has emerged as a potential therapy to slow down the progression of ALS by targeting SOD1 mRNA, representing a significant advancement in the treatment of ALS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisNeurodegenerative DiseasesAdultHumansSuperoxide Dismutase-1Oligonucleotides

Stichwörter der Autor:innen

ALSFDA-approved drugsadverse drug reactionsamyotrophic lateral sclerosisclinical trialtofersen

Substanzen

tofersenSuperoxide Dismutase-1Oligonucleotides

Autor:innen und Institutionen

  • Department of Pharmaceutical Analysis, ISF College of Pharmacy, Moga, Punjab, India.

ORCID-Profile: Pooja A Chawla

Zitieren

APA

Saini, A., & Chawla, P. A. (2024). Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis. European Journal of Neurology, 31(2). https://doi.org/10.1111/ene.16140

Vancouver

Saini A, Chawla PA. Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis. European Journal of Neurology. 2024;31(2). doi:10.1111/ene.16140

BibTeX
@article{Saini2024,
  author = {Saini, Aniket and Chawla, Pooja A},
  title = {Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {2},
  doi = {10.1111/ene.16140}
}
Kostenlos starten →